Objective:To analyze the mutation of 5′ noncoding region of BCL 6 gene in extranodal diffuse large B cell lymphoma (DLBCL) and the relationship between mutation and clinical characteristics.Methods:Extract DNA from paraffin bedded extranodal DLBCL cases,then PCR and sequenced.Meanwhile retrospective analysis was done.Results:The mutation rate was 13 64%(6/44).The clinical characteristics,such as age、sex、B symptom、bulky tumor mass、stage、the level of LDH、BM involvement and CR,had no significant influence on BCL 6 mutation;the survive time of DLBCL with/without BCL 6 mutation had no obvious difference,but there was a tendency the survival time of mutated patients was longer than that of non mutated (the mean survival time was 74 and 65 02 months,respectively);mutation wasn't an independent prognostic factor.Conclusion:The mutation of 5′ noncoding region of BCL 6 gene maybe partly involves in the mechanism of extranodal DLBCL. [

Objective:To evaluate the efficacy and safety of deoxyribonucleotide in intervention with solid tumor. Methods:A exper-imental study and randomized clinical trial were conducted. Experimental study part: MTT assay and S-180 sarcoma method were launched to observe whether the deoxyribonucleotide would affect the tumor growth. Clinical study part:86 patients of lung cancer, gastric cancer, colorectal cancer, liver cancer were divided into control group(n=43) and treatment group (n=43). Both group were given routine therapy,and the treatment group were given deoxyribonucleotide at the same time. Bone marrow suppression and live function were assessed after chemotherapy. Results:Chemotherapy Clinical effect did not improved in Deoxyribonucleotide group (47. 5% vs 44. 9%, P>0. 05), however, theⅢ-Ⅳbone,NKcellswere improved by deoxyribonucleotide (P<0. 05). What is more, the live injury of treat-ment group were less than the control group. Conclusion:Deoxyribonucleotide can decrese the occurace rate of live injury and bone mar-row suppression.

BACKGROUND: Immune checkpoint inhibitors (ICIs) have good efficacy on most advanced tumors, which brings new hope to patients with advanced tumors. However, the immune system activated by ICIs may attack human normal tissues and organs, resulting in corresponding immunotoxicity, such as checkpoint inhibitor pneumonitis. This article carried out a meta-analysis on the incidence and risk of programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) inhibitor-associated pneumonia in advanced tumors patients. METHODS: The computer retrieval of PubMed, Cochrane Library, EMbase and CNKI was performed, and the studies on the occurrence rate of PD-1/PD-L1 inhibitor-associated pneumonia in terminal cancer patients were collected, with the retrieval time limit of January 2000 to January 2020. Statistical analysis was conducted by using Revman 5.3 and R 3.6.2 software to compare the occurrence rate of pneumonia under different circumstances. RESULTS: 15 studies were included, involving 8,642 patients, of which those with PD-1/PD-L1 inhibitor were treatment group, and those with chemotherapy were control group. The odds radio of all grades of immune pneumonia was 6.63, and that of high grade was 4.87. The occurrence rate of all grades of pneumonia in the ICI group with non-small cell lung cancer (NSCLC) was 1.658 times than other tumors, and that of high grade was 2.299 times. The occurrence rate of all grades of pneumonia in second-line or more treatment with ICI was 0.489 times than that in first-line, and that of high grade was 0.449 times than that in first-line or more treatment with ICI. CONCLUSIONS Compared with chemotherapy, the risk of immune-associated pneumonia is higher in PD-1 and PD-L1 inhibitors, and its occurrence risk is high in the ICI group with NSCLC and the first-line treatment with ICI. This paper provides guidance for clinic treatment of terminal cancers and prevention of complications.